Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth (Status and Outlook) 2025-2031
Description
The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size is predicted to grow from US$ 6394 million in 2025 to US$ 31580 million in 2031; it is expected to grow at a CAGR of 30.5% from 2025 to 2031.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient"s T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
LPI (LP Information)' newest research report, the “Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Forecast” looks at past sales and reviews total world Chimeric Antigen Receptor (CAR) T-Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor (CAR) T-Cell Therapy sales for 2025 through 2031. With Chimeric Antigen Receptor (CAR) T-Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.
This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chimeric Antigen Receptor (CAR) T-Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chimeric Antigen Receptor (CAR) T-Cell Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor (CAR) T-Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor (CAR) T-Cell Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
CD19-targeted
BCMA-targeted
Segmentation by Application:
Lymphoma
Multiple Myeloma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Please note: The report will take approximately 2 business days to prepare and deliver.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient"s T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
LPI (LP Information)' newest research report, the “Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Forecast” looks at past sales and reviews total world Chimeric Antigen Receptor (CAR) T-Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor (CAR) T-Cell Therapy sales for 2025 through 2031. With Chimeric Antigen Receptor (CAR) T-Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.
This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chimeric Antigen Receptor (CAR) T-Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chimeric Antigen Receptor (CAR) T-Cell Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor (CAR) T-Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor (CAR) T-Cell Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
CD19-targeted
BCMA-targeted
Segmentation by Application:
Lymphoma
Multiple Myeloma
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
104 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Player
- 4 Chimeric Antigen Receptor (CAR) T-Cell Therapy by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
